SCHEMBL3109565

SCHEMBL3109565

O=C(NCC(F)(F)F)c1ccc(-n2cc(C(=O)NC3CC3)nn2)c(CCCCc2ccccc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 3/20 0.41
ACKR3 P25106 1/20 0.40
ENPP2 Q13822 1/20 0.39
ATXN2 Q99700 1/20 0.39
MLYCD O95822 2/20 0.39
FAAH O00519 1/20 0.37
MGLL Q99685 1/20 0.37
NAMPT P43490 1/20 0.37
BRD4 O60885 2/20 0.37
EPHX1 P07099 1/20 0.37
MAPK14 Q16539 1/20 0.36
MIF P14174 1/20 0.36
KDM4E B2RXH2 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
SMYD2 Q9NRG4 1/20 0.36
GLS O94925 1/20 0.36
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13182864 0.95 ACKR3 (0.41) DRD4ACKR3ENPP2ATXN2MLYCD
SCHEMBL3107189 0.91 ACKR3 (0.42) ACKR3MAPK14GLSRIPK1
SCHEMBL3115592 0.90 ACKR3 (0.41) ACKR3MAPK14GLSRIPK1
SCHEMBL3114865 0.90 ACKR3 (0.42) ACKR3MAPK14GLSRIPK1
SCHEMBL3103956 0.89 DRD4 (0.42) DRD4ACKR3ENPP2ATXN2FAAH
SCHEMBL13182966 0.88 ACKR3 (0.43) ACKR3MAPK14GLSRIPK1
SCHEMBL3099940 0.88 ACKR3 (0.39) DRD4ACKR3ENPP2ATXN2FAAH
SCHEMBL13182992 0.86 ACKR3 (0.44) ACKR3MAPK14GLS
SCHEMBL3113544 0.84 ACKR3 (0.38) DRD4ACKR3BRD4MAPK14MIF
SCHEMBL3109536 0.82 ACKR3 (0.45) ACKR3MAPK14GLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 EP disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 DRD4 2160/4885ACKR3 122/4885ENPP2 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.